Related Technologies: N/A.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology | Immunology.
Development Stage: Pre-clinical (*in vivo* validation).
Publications:
• Tiwary S. Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment. *https://doi.org/10.4049/jimmunol.210.Supp.172.18.*
• Tiwary, S., K. Hsu, K.C. Goldfarbmuren, Z. Xia, and J.A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. *Cancer Immunology Research,* in press.
Patents: PCT/US2024/049057, filed September 27, 2024.
Potential Commercial Applications:
• Cancer immunotherapy.
• Development of human DC vaccines.
• Formulations involving omega-3 fatty acids or pro-resolving lipids.
Competitive Advantages:
• Production of DCs with enhanced antigen-presenting function, anti-tumor efficacy and potency.
• Significant tumor reduction and improved survival compared in animals compared with wild-type DCs Potentially clinically safer than classic IMiDs by lower risk of fetal malformations.
Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for the development of NCI's compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines by using omega-3 fatty acids or pro-resolving lipid mediators.

Dated: June 23, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–12842 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for License: C8166–45 Cell Line

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166–45, transformed by HTLV–1. C8166–45, also known as C63/CRII–2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.

FOR FURTHER INFORMATION CONTACT: Inquiries related to this license opportunity should be directed to: Diptadip Dattaroy, Ph.D., Technology Transfer Manager, NCI, Technology Transfer Center, Email: *diptadip.dattaroy@nih.gov* or Phone: 240–276–7092.

SUPPLEMENTARY INFORMATION: Human T-cell leukemia virus type 1 (HTLV–1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV–1 infection has ceased. Thus, the C8166–45 cell line is a necessary component for understanding the mechanisms of HTLV–1 infection and improving clinical outcomes.

NCI researchers derived C8166–45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV–1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. This cell line is highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.

''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''
NIH Reference Number: E–272–2007.
Related Technologies: N/A.
Product Type: Research Material/Tool.
Therapeutic Area(s): Infectious Disease | Oncology.
Development Stage: Fully developed.
Publications:
• Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453).
• Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID *28970045*).
Patents: N/A.
Potential Commercial Applications:
• Investigation of HTLV pathogenesis and replication.
• Studies of virus-induced T-cell transformation.
• Studies of HTLV expression regulation by human T-cells.
• Studies of HIV replication.
Competitive Advantages:
• Contains a low amount of viral proteins.
• Does not release detectable virus particles.
• Suitable for testing RCL assay sensitivity.
Collaboration Opportunity: NCI is seeking parties to non-exclusively license the C8166–45 cell line.

Dated: June 23, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–12843 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, Members Conflict-Neurosensory Systems, July 10, 2026, 09:30 a.m. to July 10, 2026, 04:30 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda MD, 20892 which was published in the **Federal Register** on June 09, 2026, 91 FR 34827, Doc. No. 2026–11503.

This meeting is being amended to change the contact person from Kaushik Ray to Eric Tucker, Ph.D., Scientific Review Officer, Center for Scientific Review, NIH, 6701 Rockledge Drive, Bethesda, MD 20892, Ph. (301) 827–0799. The meeting is closed to the public.

Dated: June 22, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–12772 Filed 6–24–26; 8:45 am]

BILLING CODE 4167–05–P

INTERNATIONAL TRADE COMMISSION

Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has received a complaint entitled *Certain Adjustable Child*